Brooklyn ImmunoTherapeutics, Inc. (BTX)
- GlobeNewswire
Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
Company has expanded team with scientific hires who hold research expertise in stem cells, synthetic RNA, nanoparticle delivery systems and immunologySAN DIEGO, April 21, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the establishment
- GlobeNewswire
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the fourth quarter and year ended December 31, 2021. Financial and corporate highlights for the quarter and year months ended December 31, 2021 and subsequently includ
- GlobeNewswire
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it has closed its previously announced private placement with a leading healthcare investor. The gross proceeds to Brooklyn from the private placement, before deducting the placement ag
